Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kimball Electronics Reports Q3 Results and Reiterates Guidance for Fiscal 2025 With Sales and Operating Income Expected at High-End of Range; Company Adds New Facility to Support Strategy to Drive Growth in the Medical CMO

KE

Third Quarter Fiscal 2025 Highlights

  • Net sales totaled $374.6 million
  • Operating income of $11.7 million, or 3.1% of net sales, adjusted operating income of 4.2%
  • Inventory of $296.6 million, a reduction of $9.6 million from Q2
  • Cash generated by operating activities of $30.9 million, the fifth consecutive quarter of positive cash flow
  • Borrowings on credit facilities of $178.8 million, a $26.2 million decrease from the second quarter, and down $116 million, or 40%, in the fiscal year

Kimball Electronics, Inc. (Nasdaq: KE) today announced financial results for the third quarter ended March 31, 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506973868/en/

Three Months Ended

Nine Months Ended

March 31,

March 31,

(Amounts in Thousands, except EPS)

2025

2024

2025

2024

Net Sales

$

374,607

$

425,036

$

1,106,255

$

1,284,352

Operating Income

$

11,716

$

(6,431

)

$

29,061

$

29,669

Adjusted Operating Income (non-GAAP) (1)

$

15,706

$

18,733

$

41,629

$

58,802

Operating Income %

3.1

%

(1.5

)%

2.6

%

2.3

%

Adjusted Operating Income (non-GAAP) %

4.2

%

4.4

%

3.8

%

4.6

%

Net Income

$

3,817

$

(6,076

)

$

10,403

$

12,968

Adjusted Net Income (non-GAAP) (1)

$

6,837

$

9,786

$

19,718

$

31,607

Diluted EPS

$

0.15

$

(0.24

)

$

0.41

$

0.51

Adjusted Diluted EPS (non-GAAP) (1)

$

0.27

$

0.39

$

0.79

$

1.25

(1)

Beginning in the first quarter of fiscal year 2025, adjusted results exclude stock compensation expense. Prior reported periods have been revised accordingly. A reconciliation of GAAP and non-GAAP financial measures is included below.

Commenting on today’s announcement, Richard D. Phillips, Chief Executive Officer, stated, “I’m proud of the results for the third quarter and our team’s ability to navigate an environment of uncertainty, while focusing on what is controllable. Sales in Q3 were in line with expectations, margins improved sequentially, cash generated from operating activities was positive for the fifth consecutive quarter, and the paydown of debt continued with borrowings now 45% lower than peak levels. We have ample liquidity to weather short-term unpredictability and significant dry powder to opportunistically invest in the business.”

Mr. Phillips continued, “As part of today’s release, we are reiterating our guidance for fiscal 2025 with an expectation of sales and operating income at the high-end of the range, as well as, announcing the addition of a new manufacturing facility in Indianapolis focused on the medical industry. This is another step of repositioning the Company for a return to growth and expanding our medical CMO strategy.”

The Company ended the third quarter of fiscal 2025 with cash and cash equivalents of $51.4 million and borrowing capacity available of $253.2 million. Capital expenditures were $4.0 million, and the company invested $3.0 million to repurchase 175,000 shares of common stock.

Net Sales by Vertical Market for Q3 Fiscal 2025:

Three Months Ended

Nine Months Ended

March 31,

March 31,

(Amounts in Millions)

2025

*

2024

*

Percent

Change

2025

*

2024

*

Percent Change

Automotive

$

173.1

46

%

$

202.0

47

%

(14

)%

$

554.3

50

%

$

614.7

48

%

(10

)%

Medical

115.2

31

%

113.0

27

%

2

%

288.9

26

%

323.5

25

%

(11

)%

Industrial excluding AT&M (1)

86.3

23

%

101.9

24

%

(15

)%

261.0

24

%

315.3

25

%

(17

)%

Net Sales excluding AT&M (1)

$

374.6

100

%

$

416.9

98

%

(10

)%

$

1,104.2

100

%

$

1,253.5

98

%

(12

)%

AT&M (1)

%

8.1

2

%

(100

)%

2.1

%

30.9

2

%

(93

)%

Total Net Sales

$

374.6

100

%

$

425.0

100

%

(12

)%

$

1,106.3

100

%

$

1,284.4

100

%

(14

)%

* As a percent of Total Net Sales

(1) Sales from our Automation, Test, and Measurement business (AT&M), which was divested effective July 31, 2024, were previously included in the Industrial vertical

Automotive includes electronic power steering, body controls, automated driver assist systems, and electronic braking systems

Medical includes sleep therapy and respiratory care, image guided therapy, in vitro diagnostics, drug delivery, AED, and patient monitoring

Industrial includes climate controls, automation controls, and public safety

Company Guidance for Fiscal Year 2025

The Company expects to be at the high-end of its guidance range for both net sales and adjusted operating income. The range for net sales is $1.40 - $1.44 billion, while the range for adjusted operating income(a) is 3.4% - 3.6% of net sales. Capital expenditures are estimated to be at the low-end of the guidance range of $40 - $50 million.

(a)

Fiscal year 2025 guidance reflects a change in our adjusted operating income calculation beginning in fiscal year 2025, which excludes stock compensation expense. This change better aligns our presentation with others in our industry. A reconciliation of GAAP and non-GAAP financial measures is included below.

Forward-Looking Statements

Certain statements contained within this release are considered forward-looking, including our guidance, under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as “expect,” “should,” “goal,” “predict,” “will,” “future,” “optimistic,” “confident,” and “believe.” Undue reliance should not be placed on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These forward-looking statements are subject to risks and uncertainties including, without limitation, global economic conditions, geopolitical environment and conflicts such as the war in Ukraine, global health emergencies, availability or cost of raw materials and components, tariffs and other trade barriers, foreign exchange rate fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of the company are contained in its Annual Report on Form 10-K for the year ended June 30, 2024.

Non-GAAP Financial Measures

This press release contains non-GAAP financial measures. The non-GAAP financial measures contained herein include constant currency growth, net sales excluding Automation, Test & Measurement, adjusted selling and administrative expenses, adjusted operating income, adjusted net income, adjusted diluted EPS, and ROIC. Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included in the Reconciliation of Non-GAAP Financial Measures section below. Management believes these measures are useful and allow investors to meaningfully trend, analyze, and benchmark the performance of the company’s core operations. The company’s non-GAAP financial measures are not necessarily comparable to non-GAAP information used by other companies.

About Kimball Electronics, Inc.

Kimball Electronics is a global, multifaceted manufacturer offering Electronics Manufacturing Services (EMS) and Contract Manufacturing Organization (CMO) solutions to customers around the world. From our operations in the United States, China, Mexico, Poland, Romania, and Thailand, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana.

To learn more about Kimball Electronics, visit www.kimballelectronics.com.

Conference Call / Webcast

Date:

May 7, 2025

Time:

10:00 AM Eastern Time

Live Webcast:

investors.kimballelectronics.com/events-and-presentations/events

Dial-In #:

877-407-8293 (or 201-689-8349)

For those unable to participate in the live webcast, the call will be archived at investors.kimballelectronics.com.

Lasting relationships. Global success.

Financial highlights for the third quarter and year-to-date period ended March 31, 2025 are as follows:

Condensed Consolidated Statements of Income

(Unaudited)

Three Months Ended

(Amounts in Thousands, except Per Share Data)

March 31, 2025

March 31, 2024

Net Sales

$

374,607

100.0

%

$

425,036

100.0

%

Cost of Sales

347,711

92.8

%

391,492

92.1

%

Gross Profit

26,896

7.2

%

33,544

7.9

%

Selling and Administrative Expenses

13,154

3.6

%

16,861

3.9

%

Other General Expense (Income)

%

(892

)

(0.2

)%

Restructuring Expense

2,026

0.5

%

1,622

0.4

%

Goodwill Impairment

%

5,820

1.4

%

Asset Impairment (Gain on Disposal)

%

16,564

3.9

%

Operating Income

11,716

3.1

%

(6,431

)

(1.5

)%

Interest Income

100

%

83

%

Interest Expense

(2,936

)

(0.8

)%

(5,875

)

(1.4

)%

Non-Operating Income (Expense), net

(1,726

)

(0.4

)%

(530

)

(0.1

)%

Other Income (Expense), net

(4,562

)

(1.2

)%

(6,322

)

(1.5

)%

Income Before Taxes on Income

7,154

1.9

%

(12,753

)

(3.0

)%

Provision (Benefit) for Income Taxes

3,337

0.9

%

(6,677

)

(1.6

)%

Net Income (Loss)

$

3,817

1.0

%

$

(6,076

)

(1.4

)%

Earnings Per Share of Common Stock:

Basic

$

0.15

$

(0.24

)

Diluted

$

0.15

$

(0.24

)

Average Number of Shares Outstanding:

Basic

24,728

25,118

Diluted

24,872

25,118

(Unaudited)

Nine Months Ended

(Amounts in Thousands, except Per Share Data)

March 31, 2025

March 31, 2024

Net Sales

$

1,106,255

100.0

%

$

1,284,352

100.0

%

Cost of Sales

1,032,332

93.3

%

1,180,833

91.9

%

Gross Profit

73,923

6.7

%

103,519

8.1

%

Selling and Administrative Expenses

37,107

3.4

%

50,736

4.0

%

Other General Expense (Income)

%

(892

)

(0.1

)%

Restructuring Expense

9,019

0.8

%

1,622

0.1

%

Goodwill Impairment

%

5,820

0.5

%

Asset Impairment (Gain on Disposal)

(1,264

)

(0.1

)%

16,564

1.3

%

Operating Income

29,061

2.6

%

29,669

2.3

%

Interest Income

575

0.1

%

483

%

Interest Expense

(11,969

)

(1.1

)%

(17,459

)

(1.4

)%

Non-Operating Income (Expense), net

(4,155

)

(0.4

)%

(959

)

%

Other Income (Expense), net

(15,549

)

(1.4

)%

(17,935

)

(1.4

)%

Income Before Taxes on Income

13,512

1.2

%

11,734

0.9

%

Provision (Benefit) for Income Taxes

3,109

0.3

%

(1,234

)

(0.1

)%

Net Income

$

10,403

0.9

%

$

12,968

1.0

%

Earnings Per Share of Common Stock:

Basic

$

0.42

$

0.52

Diluted

$

0.41

$

0.51

Average Number of Shares Outstanding:

Basic

24,859

25,084

Diluted

25,047

25,263

Condensed Consolidated Statements of Cash Flows

Nine Months Ended

(Unaudited)

March 31,

(Amounts in Thousands)

2025

2024

Net Cash Flow provided by Operating Activities

$

105,870

$

24,717

Net Cash Flow used for Investing Activities

(5,160

)

(37,702

)

Net Cash Flow (used for) provided by Financing Activities

(126,615

)

36,571

Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash

13

(113

)

Net (Decrease) Increase in Cash, Cash Equivalents, and Restricted Cash

(25,892

)

23,473

Cash, Cash Equivalents, and Restricted Cash at Beginning of Period

78,779

43,864

Cash, Cash Equivalents, and Restricted Cash at End of Period

$

52,887

$

67,337

(Unaudited)

Condensed Consolidated Balance Sheets

March 31,
2025

June 30,
2024

(Amounts in Thousands)

ASSETS

Cash and cash equivalents

$

51,377

$

77,965

Receivables, net

251,138

282,336

Contract assets

78,378

76,320

Inventories

296,602

338,116

Prepaid expenses and other current assets

29,808

44,682

Assets held for sale

27,587

Property and Equipment, net

268,351

269,659

Goodwill

6,191

6,191

Other Intangible Assets, net

2,601

2,994

Other Assets, net

90,109

82,069

Total Assets

$

1,074,555

$

1,207,919

LIABILITIES AND SHARE OWNERS EQUITY

Current portion of long-term debt

$

28,900

$

59,837

Accounts payable

215,430

213,551

Advances from customers

39,676

30,151

Accrued expenses

46,951

63,189

Liabilities held for sale

8,594

Long-term debt, less current portion

149,376

235,000

Long-term income taxes payable

3,255

Other long-term liabilities

46,107

53,881

Share Owners’ Equity

548,115

540,461

Total Liabilities and Share Owners’ Equity

$

1,074,555

$

1,207,919

Other Financial Metrics

(Unaudited)

(Amounts in Millions, except CCD)

At or For the

Three Months Ended

March 31,

December 31,

March 31,

2025

2024

2024

Depreciation and Amortization

$

9.2

$

9.1

$

10.5

Cash Conversion Days (CCD) (1)

99

107

110

Open Orders (2)

$

642

$

564

$

831

(1)

Cash Conversion Days (“CCD”) are calculated as the sum of Days Sales Outstanding plus Contract Asset Days plus Production Days Supply on Hand less Accounts Payable Days and less Advances from Customers Days. CCD, or a similar metric, is used in our industry and by our management to measure the efficiency of managing working capital.

(2)

Open Orders are the aggregate sales price of production pursuant to unfulfilled customer orders. Our declining open orders are primarily due to the cancellation of a major automotive program and other demand reductions, as well as reduced lead times on customer orders as compared to March 31, 2024, when parts were more constrained.

Select Financial Results of Automation, Test and Measurement

(Unaudited)

(Amounts in Millions)

Three Months Ended

Nine Months Ended

March 31,

March 31,

2025

2024

2025

2024

Net Sales

$

$

8.1

$

2.1

$

30.9

Operating Income (Loss) (1)

$

$

(25.4

)

$

0.8

$

(24.3

)

(1)

Includes gain on sale of $1.3 million following the close of the sale on July 31, 2024 for the nine months ended March 31, 2025. Includes goodwill impairment of $5.8 million and asset impairment of $16.6 million for the three and nine months ended March 31, 2024. Each period also includes allocated corporate overhead expenses.

Reconciliation of Non-GAAP Financial Measures

(Unaudited, Amounts in Thousands, except Per Share Data)

Three Months Ended

Nine Months Ended

March 31,

March 31,

2025

2024

2025

2024

Net Sales Growth (vs. same period in prior year)

(12

)%

(12

)%

(14

)%

(3

)%

Foreign Currency Exchange Impact

(1

)%

%

%

%

Constant Currency Growth

(11

)%

(12

)%

(14

)%

(3

)%

Selling and Administrative Expenses, as reported

$

13,154

$

16,861

$

37,107

$

50,736

Stock Compensation Expense

(1,955

)

(1,773

)

(4,528

)

(5,435

)

SERP

(9

)

(277

)

(285

)

(584

)

Adjusted Selling and Administrative Expenses

$

11,190

$

14,811

$

32,294

$

44,717

Operating Income (Loss), as reported

$

11,716

$

(6,431

)

$

29,061

$

29,669

Stock Compensation Expense

1,955

1,773

4,528

5,435

SERP

9

277

285

584

Legal Settlements (Recovery)

(892

)

(892

)

Restructuring Expense

2,026

1,622

9,019

1,622

Goodwill Impairment

5,820

5,820

Asset Impairment (Gain on Disposal)

16,564

(1,264

)

16,564

Adjusted Operating Income

$

15,706

$

18,733

$

41,629

$

58,802

Net Income (Loss), as reported

$

3,817

$

(6,076

)

$

10,403

$

12,968

Stock Compensation Expense, After-Tax

1,483

1,345

3,434

4,122

Legal Settlements (Recovery), After-Tax

(676

)

(676

)

Restructuring Expense, After-Tax

1,537

1,230

6,840

1,230

Goodwill Impairment, After-Tax

4,414

4,414

Asset Impairment (Gain on Disposal), After-Tax

9,549

(959

)

9,549

Adjusted Net Income

$

6,837

$

9,786

$

19,718

$

31,607

Diluted Earnings per Share, as reported

$

0.15

$

(0.24

)

$

0.41

$

0.51

Stock Compensation Expense

0.06

0.05

0.14

0.16

Legal Settlements (Recovery)

(0.03

)

(0.03

)

Restructuring Expense

0.06

0.05

0.27

0.05

Goodwill Impairment

0.18

0.18

Asset Impairment (Gain on Disposal)

0.38

(0.03

)

0.38

Adjusted Diluted Earnings per Share

$

0.27

$

0.39

$

0.79

$

1.25

Twelve Months Ended

March 31,

2025

2024

Operating Income

$

48,669

$

61,118

Goodwill Impairment

5,820

SERP

381

827

Restructuring Expense

9,783

1,622

Asset Impairment (Gain on Disposal)

(788

)

16,564

Legal Settlements (Recovery)

(1,104

)

Stock Compensation Expense

6,278

6,992

Adjusted Operating Income (non-GAAP)

$

64,323

$

91,839

Tax Effect

20,174

21,698

After-tax Adjusted Operating Income

$

44,149

$

70,141

Average Invested Capital (1)

$

726,208

$

783,059

ROIC

6.1

%

9.0

%

(1)

Average invested capital is computed using Share Owners’ equity plus current and non-current debt less cash and cash equivalents averaged for the last five quarters.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today